scholarly journals Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer

The Prostate ◽  
2021 ◽  
Author(s):  
Elisa M. Ledet ◽  
Earle F. Burgess ◽  
Alexandra O. Sokolova ◽  
Ellen B. Jaeger ◽  
Whitley Hatton ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
African American ◽  
Metastatic Prostate Cancer ◽  
Germline Mutations ◽  
Caucasian Men

Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 5568-5568
Author(s):  
Elisa Marie Ledet ◽  
Ellen Jaeger ◽  
Whitley Hatton ◽  
Marcus W. Moses ◽  
Alexandra Sokolova ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Dna Repair ◽  
African American ◽  
Family History ◽  
Metastatic Prostate Cancer ◽  
Germline Mutations ◽  
Dna Repair Genes ◽  
Brca Mutations ◽  
Repair Genes

5568 Background: The relevance of germline mutations in metastatic prostate cancer is well established; however, comparison of germline genetics in African American (AA) versus Caucasian (CA) men with metastatic prostate cancer (PCa) is limited. Methods: Germline data from self-identified AA and CA metastatic PCa patients (pts) were collected from 5 academic cancer centers. Various commercial cancer-specific germline testing panels were used to evaluate 12-86 genes. Pathogenic (P) or likely pathogenic (LP) mutations, and variants of unknown significance (VUS), were reported according to ACMG guidelines. Self-reported family history (FH) was annotated for 99% of pts. Statistical analyses included Chi-squared and Fischer’s exact tests. Results: A total of 821 metastatic PCa pts were assessed: 152 AAs and 669 CAs. For P/LP alterations, AAs had a frequency of 11.2% (17/152) as compared to a frequency of 14.6% (98/669) in CAs (p = 0.302). AA pts were more likely to have a VUS than CA pts, 61% vs 43% respectively (OR = 2.09, 95%CI [1.45, 2.99], p < 0.001). BRCA mutations were similar between races, but AA were more likely to have a BRCA1 P/LP alteration (OR = 6.00, 95% CI [1.33, 27.09], p = 0.025). AA pts were less likely to have a P/LP alteration in a non-BRCA gene (OR = 0.34, 95% CI [0.15, 0.80], p = 0.013). Among DNA repair genes, there were no significant difference between AA and CA pts (p = 0.574); however, there was a trend toward AA pts having fewer P/LP alteration in a non-BRCA DNA repair genes (OR = 0.26, 95% CI [0.06, 1.08], p = 0.071). In pts with >1 first degree relative (FDR) with ovarian cancer, P/LP germline alterations were more likely in CAs (OR = 2.33, 95% CI [1.05, 5.17], p = 0.043); but there were no significant differences in AAs (p = 0.098). Those with >2 FDRs with PCa were more likely to have a P/LP change in CAs (OR = 2.32, 95% CI [1.04, 5.15], p = 0.043), but there were no difference in AAs (p = 0.700). In pts with ≥2 FDRs with breast cancer, P/LP germline alterations were more likely in both AAs (OR = 9.36, 95% CI [1.72, 50.84], p = 0.019) and CAs (OR = 3.92, 95% CI [1.79, 8.59], p = 0.001). Conclusions: We did not observe a difference in the overall frequency of germline P/LP alterations between AA and CA men with metastatic PCa but VUSs were more common in AA men. These AA men have an overall frequency of BRCA mutations similar to CA men; however, BRCA1 mutations were more prevalent in these AAs. Non-BRCA P/LP mutations are significantly less frequent in AA pts. A positive family history of >2 FDRs with breast cancer was associated with P/LP alterations in both AA and CA pts.

Abstract C10: Immunoseroproteomic profiling of autoantibodies to tumor-associated autoantigens in African American and Caucasian men with prostate cancer

2014 ◽  
Author(s):  
Tino W. Sanchez ◽  
Saied Mirshahidi ◽  
Nathan R. Wall ◽  
Colwick Wilson ◽  
Susanne Montgomery ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
African American ◽  
Caucasian Men

scholarly journals Genome-wide differentially methylated genes in prostate cancer tissues from African-American and Caucasian men

Epigenetics ◽  
2015 ◽  
Vol 10 (4) ◽  
pp. 319-328 ◽  
Author(s):  
JM Devaney ◽  
S Wang ◽  
P Furbert-Harris ◽  
V Apprey ◽  
M Ittmann ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
African American ◽  
Genome Wide ◽  
Differentially Methylated Genes ◽  
Caucasian Men ◽  
Cancer Tissues

Genetic counseling processes and outcomes among prostate cancer patients (ProGen).

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. TPS343-TPS343 ◽  
Author(s):  
Donna Rachel Vatnick ◽  
Sandjida Aktar ◽  
Jill E. Stopfer ◽  
Lindsay Kipnis ◽  
Samantha K. Culver ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Dna Repair ◽  
Genetic Counseling ◽  
Genetic Testing ◽  
Cancer Risk ◽  
Mismatch Repair ◽  
Metastatic Prostate Cancer ◽  
Germline Mutations ◽  
Mismatch Repair Genes ◽  
Repair Genes

TPS343 Background: Prostate cancer (PC) is among the leading causes of cancer mortality in males. Recent studies found 8-12% of advanced PC cases may be hereditary. Germline mutations have been reported in BRCA1/2, other DNA repair genes including ATM, CHEK2, PALB2 and DNA mismatch repair genes. Genetic testing can inform treatment decisions including drug targeting, such as PARP inhibitors for men with BRCA mutations, and checkpoint inhibitors for those with pathogenic mutations in mismatch repair genes2. Discovering a pathogenic mutation associated with increased cancer risk also prompts dissemination of this information to family, where subsequent testing can lead to risk stratification and impactful opportunities for cancer screening and prevention. It is critical that men with high risk and potentially lethal prostate cancer routinely be offered genetic testing as a component of their cancer care. Genetic counseling services are limited, and more efficient services are needed. Methods: We are investigating video education prior to genetic testing compared with in-person pretest counseling with a licensed genetic counselor (GC). ProGen is an ongoing randomized trial evaluating two distinct models of cancer genetics service delivery in 450 PC cases over a two-year period. The study is conducted in collaboration with Ambry Genetics utilizing a 67-gene cancer panel. The primary aim is analysis of the proportion and type of germline mutations identified. Secondary aims include testing uptake by arm, evaluation of distress, knowledge, satisfaction with testing services, family communication, and impact on cancer care. Results are communicated by telephone with a GC. Inclusion criteria are: potentially lethal PC (metastatic, localized with Gleason score ≥8, rising/persistent PSA after local therapy), early diagnosis (≤ 55 years), prior malignancy, and/or family history potentially indicating a hereditary cancer risk. Enrollment is 74% completed at a single institution. (NCT03328091). 1 Pritchard CC, et al. Inherited DNA‐repair gene mutations in men with metastatic prostate cancer. NEJM. 2016;375:443 2 Mateo J, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. NEJM . 2015;373(18):1697-1708 Clinical trial information: NCT03328091.

scholarly journals African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men

2015 ◽  
Vol 33 (2) ◽  
pp. 70.e15-70.e22 ◽  
Author(s):  
Kosj Yamoah ◽  
Curtiland Deville ◽  
Neha Vapiwala ◽  
Elaine Spangler ◽  
Charnita M. Zeigler-Johnson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
African American ◽  
African American Men ◽  
Disease Recurrence ◽  
Low Grade ◽  
Caucasian Men

Obesity and prostate cancer screening among african-american and caucasian men

The Prostate ◽  
2006 ◽  
Vol 66 (13) ◽  
pp. 1371-1380 ◽  
Author(s):  
Jay H. Fowke ◽  
Lisa B. Signorello ◽  
Willie Underwood ◽  
Flora A.M. Ukoli ◽  
William J. Blot
Keyword(s):  
Prostate Cancer ◽  
African American ◽  
Cancer Screening ◽  
Prostate Cancer Screening ◽  
Caucasian Men

scholarly journals RESPONSE: Re: Association of African-American Ethnic Background With Survival in Men With Metastatic Prostate Cancer

2001 ◽  
Vol 93 (15) ◽  
pp. 1175-1175 ◽  
Author(s):  
I. M. Thompson ◽  
C. M. Tangen ◽  
A. Tolcher ◽  
E. D. Crawford ◽  
M. Eisenberger ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
African American ◽  
Metastatic Prostate Cancer ◽  
Ethnic Background

Risk of more advanced cancer at surgery in African American men eligible for active surveillance.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e15214-e15214
Author(s):  
Amirali H Salmasi ◽  
Misop Han ◽  
Isaac Yi Kim
Keyword(s):  
Prostate Cancer ◽  
African American ◽  
Advanced Cancer ◽  
Active Surveillance ◽  
African American Men ◽  
Low Grade ◽  
Inclusion Criteria ◽  
Medical Institutions ◽  
Caucasian Men ◽  
Preoperative Predictors

e15214 Background: African-American (AA) men have a higher risk for developing prostate cancer (PCa) and dying of PCa compared to Caucasian men. Active surveillance (AS) is an acceptable management for males with low volume and low grade PCa. In Caucasian men who were eligible for AS, the risk of non-organ-confined disease [NOC] at radical prostatectomy (RP) ranges between 7.8 and 10.9% (Kang et al 2011, Mufarrij et al 2010). It is unclear whether AA men with favorable risk PCa can undergo AS safely. We evaluated changes in staging and grading of PCa in a cohort of AA males that met the criteria for AS but underwent RP. Methods: Between 1997 and 2011, 1536 AA men underwent RP at either Johns Hopkins Medical Institutions or Cancer Institute of New Jersey. Pathological characteristics of patients who fulfilled the inclusion criteria under the National Cancer Institute (NCI) AS criteria were examined. NOC (ECE/SV+/LN+) and upgrading (Gleason <7 in biopsy to Gleason >6 in RP) was evaluated. We tried to identify preoperative predictors of more advanced cancer (NOC and/or upgrading). Results: We identified 212 men who underwent RP, eligible for AS based on NCI criteria. Among 212 men, 92 (37.7%) men showed NOC and/or upgrading, defined SV involvement in 5 (2.4%), ECE in 53 (25%), and increased Gleason (<7 to >6) in 69 (32%) men. Pre-operative PSA level (OR 1.2, p < 0.05) and age (OR 1.06, p < 0.01) were significantly associated with more advanced cancer. No significant association was found between BMI, tissue percentage, or positive cores with more advanced cancer. Conclusions: AS in AA with prostate cancer carries higher risk of NOC compared to non-AA population. More stringent AS entrance criteria may be necessary for AA men.

Streamlining the genetics pipeline to increase testing for patients at risk for hereditary prostate cancer.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 1590-1590
Author(s):  
Barry Tong ◽  
Hala Borno ◽  
Eric Jay Small ◽  
Fern Alagala ◽  
Amie Blanco ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Genetic Testing ◽  
High Risk ◽  
Metastatic Prostate Cancer ◽  
Genetic Counselor ◽  
Germline Mutations ◽  
Genetic Counselors ◽  
High Risk Population ◽  
Risk Population ◽  
Positive Results

1590 Background: Metastatic prostate Cancer (mPCa) is increasingly recognized as a heritable disease and germline genetic testing has increasingly become a part of standard of care. At the University of California at San Francisco (UCSF) Genitourinary (GU) Medical Oncology clinic, approximately 850 new patients with mPCa are seen annually. A feasibility pilot Genetic Testing Station (GTS) was developed to expand access to genetic testing among this high-risk population. GTS is facilitated by Genetic Counselor Assistants (GCA) under the supervision of genetic counselors. Methods: This is a feasibility pilot of a GTS model among patients with mPCa. In this model, all patients with mPCa are offered a same day GTS visit with a GCA. At the GTS, the patient receives pre-test education via videos developed by genetic counselors. The patient provides informed consent, a family history, and a saliva sample for Invitae’s 87-gene panel. All positive results trigger a genetic counselor visit while non-positive results either receive a letter or a genetic counselor visit (in person or via telehealth). To evaluate the model, testing frequency and laboratory turnaround time (TAT) was assessed before and after the pilot. Results: In the first four months of the GTS pilot (10/14/2019 – 02/10/2020), 94 patients were referred and received genetic testing. Eight germline positives were identified (BRCA2, CHEK2, HOXB13 MSH6, RECQL4). The average TAT was 8 days. 9.3% of patients were found to have pathogenic mutations through the prostate GTS which is comparable to previously published rates of germline mutations in metastatic prostate cancer patients. In a 4-month time frame the prior to the intervention (10/01/2018-1/31/2019), 26 genetic testing orders were placed. The average laboratory TAT in this prior process was 17 days. Rates of positive germline mutations in the prior model was 8.6%. Conclusions: The GTS is a feasible method to increase access to germline genetic testing among a high-risk population. It may reduce barriers to testing and facilitate real-time discussion of treatment and prevention strategies with patients and family members. As a result, we will continue to operate the GTS. This model provides a framework for scaling access for and cascade testing in other high-risk patient groups.

Sign in / Sign up

Export Citation Format

Share Document